Chong Kun Dang Pharmaceutical Corporation

Chong Kun Dang Corporation

Jong Lae Lim

Min Soo Kim

Shin Jung Park

Jong Seo Choi

Jae Hyun Kim

Hee Jong Shin

Chung Il Hong

Jaehoon You

Jung Woo Kim

Young Nam Lee

Soon Kil Ahn

Min Hyo Ki

Ji Hee Lee

Nam Hee Choi

Ho Young Hwang

So Hyun Park

Su Geun Yang

Hee-Jeong Cho

Sang Myoung Noh

Ah-Reum Chae

Su Kyung Lee

Chong Kook Kim

Ki Seong Ko

Won Kyu Choi

Tae Hyun Park

The present invention relates to a pharmaceutical or food composition comprisingpretreated extract exhibiting an excellently enhanced pharmacological effect thanextract prepared by a conventional common extraction method ofand extract prepared withsingle herb medicine, or a method for preventing, improving or treating gastritis or peptic ulcer using the composition. In addition, the present invention relates to a preparation method ofpretreated extract which is characterized by pretreatingwith a non-polar solvent and extracting it with a polar solvent.

Composition for preventing or treating gastritis or peptic ulcer

The present invention relates to a pharmaceutical preparation comprising omeprazole, an enantiomer thereof or a pharmaceutically acceptable salt thereof, and sodium bicarbonate, and a method for preparing the same. Specifically, the present invention relates to a pharmaceutical preparation in which sodium bicarbonate is first disintegrated so as to raise pH, and then omeprazole is dissolved such that the release properties of an active ingredient are improved, and thus the dissolution pattern and bioavailability of a drug can be enhanced.

Pharmaceutical preparation having excellent dissolution properties, containing esomeprazole and sodium bicarbonate

The present invention relates to a stable pharmaceutical composition comprising omeprazole, its enantiomer, or its pharmaceutically acceptable salt, and sodium bicarbonate. Specifically, the present invention relates to a pharmaceutical composition with improved stability comprising a low dose of sodium bicarbonate, so that it has improved dissolution rate and bioavailability and also reduces side effects resulting from a high dose of sodium bicarbonate.

Stable pharmaceutical composition comprising esomeprazole and sodium bicarbonate

The present invention relates to a stable pharmaceutical formulation comprising omeprazole, its enantiomer, or its pharmaceutically acceptable salt, and sodium bicarbonate, and a method for preparing the same. Specifically, the present invention provides a stable formulation by preventing omeprazole, its enantiomer, or its pharmaceutically acceptable salt, from coming in direct contact with sodium bicarbonate, to reduce the production of impurities.

Pharmaceutical formulation comprising esomeprazole and sodium bicarbonate

Disclosed is a pharmaceutical composition for gene delivery, comprising: (i) a gene; (ii) a water-soluble chitosan; (iii) a thiamine pyrophosphate or a pharmaceutically acceptable salt thereof; (iv) a protamine or a pharmaceutically acceptable salt thereof; and (v) a neutral or anionic phospholipid. The composition can introduce a gene into cells safely and effectively. Composed of non-toxic and injectable components, the composition is safe for the body and can be advantageously commercialized. Notably, it can deliver a gene at high efficiency in vivo as well as in vitro, and is stable in the blood.

Composition for gene delivery

The present invention relates to an inclusion compound of fumagillol derivative or its salt with hydroxypropyl-&#x3b2;-cyclodextrin or sulfobutylether-7-&#x3b2;-cyclodextrin, and pharmaceutical compositions comprising the same. The inclusion compound according to the present invention has superior water solubility and stability while exhibiting low toxicity, rendering it valuable as an anticancer agent or inhibitor of tumor metastasis.

Inclusion compounds of fumagillol derivative or its salt, and pharmaceutical compositions comprising the same

A pharmaceutical composition comprising a cyclosporin solid-state microemulsion is disclosed. In a preferred embodiment, the composition comprises a cyclosporin microemulsion dispersed in an enteric carrier. The composition does not dissolve in external phases such as artificial gastric fluid, but dissolves rapidly in artificial intestinal fluid, whereby it releases the cyclosporin microemulsion, providing rapid delivery of cyclosporin. The composition effectively maintains a therapeutic blood concentration of cyclosporin with once a day dosing, providing for convenience of administration and avoiding adverse effects induced by increasing peak blood cyclosporin concentrations associated with conventional cyclosporin formulations.

Pharmaceutical composition comprising cyclosporin solid-state microemulsion

Growing community of inventors

Chungcheongnam-do, South Korea

Jong Lae Lim